Heartflow, known for its AI-based CCTA evaluations, appears to be going public. The news follows years of momentum for the California-based company, including improved Medicare reimbursements for cardiac CT and a new Category I CPT code for its Plaque Analysis software.

One of the study's most significant findings was that patients managed using the advanced AI software saw LDL cholesterol drops of 18.7 mg/dL, with a 15% reduction in their risk of a cardiac event. Even patients with no calcified plaque saw significant changes in care management.

The numbers from Pittsburgh are staggering. And they’re all about blasting American-made AI into the stratosphere, if not to Infinity and beyond. 

Receivers on active glucose monitors manufactured by Dexcom are reportedly failing to send alerts when a patient’s blood sugar levels are dangerously high or low. There have been no deaths linked to the malfunction.